mCRPC Prostate Cancer
Conditions
Interventions
None listed
Sponsors
LAVA Therapeutics NV
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients are eligible to be included in the study only if all of the following criteria apply: 1. Patient must be 18 years of age or above at the time of signing the informed consent. 2. Male patient with mCRPC (histologically confirmed adenocarcinoma of the prostate) as defined by Prostate Cancer Working Group 3 (PCWG3) criteria. 3. Patient should have received at least 2 lines of prior therapy in the mCRPC setting, including at least one androgen receptor pathway inhibitor (e.g., abiraterone, enzalutamide). Patients may or may not have received a taxane-based chemotherapy. Taxane-naïve patients will not exceed 20% of all patients enrolled. Patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutations should have received a Poly-ADP ribose polymerase (PARP) inhibitor.
Exclusion criteria
Exclusion criteria: Patients are excluded from the study if any of the following criteria apply: 1. Uncontrolled or severe intercurrent medical condition. 2. Adenocarcinoma with small cell or neuroendocrine features.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To investigate the frequency of Vγ9Vδ2-T cells in patients with metastatic castration-resistant prostate cancer. | — |
Secondary
| Measure | Time frame |
|---|---|
| To investigate any correlations between the frequency of Vγ9Vδ2-T cells and clinical characteristics. To investigate any correlations between the frequency of Vγ9Vδ2-T cells and treatment history. | — |
Countries
Netherlands
Outcome results
None listed